Analysts Adjust Ratings and Targets for Gossamer Bio

The clinical-stage biotech company faces changes in analyst coverage.

Mar. 16, 2026 at 11:38pm

Got story updates? Submit your updates here. ›

Several major brokerages have updated their recommendations and price targets for shares of Gossamer Bio (NASDAQ: GOSS), a clinical-stage biopharmaceutical company headquartered in San Diego, California. Gossamer Bio is focused on developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications.

Why it matters

Analyst ratings and price targets can significantly impact investor sentiment and trading activity around a stock, especially for a clinical-stage biotech company like Gossamer Bio that relies heavily on investor confidence in its pipeline and future prospects.

The details

The recent analyst updates cover Gossamer Bio's lead programs, including GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. These changes in analyst coverage reflect the evolving landscape and market expectations for Gossamer Bio's drug candidates.

  • The analyst updates occurred over the last few weeks, with the most recent changes reported on 3/6/2026.

The players

Gossamer Bio, Inc.

A clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications.

HC

A brokerage firm that recently lowered its price target for Gossamer Bio.

Got photos? Submit your photos here. ›

The takeaway

The analyst updates on Gossamer Bio reflect the ongoing scrutiny and evolving market expectations for the company's drug pipeline, which will be crucial for investors to monitor as the company continues its clinical development efforts.